Review of neoadjuvant chemotherapy and trachelectomy: which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery?

Abstract:

:The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing procedure can be included in studies with NAC followed by fertility-sparing procedure. We must consider that both oncological and pregnancy outcomes are important. Patients with only microscopic disease after NAC are apparently the best candidates for fertility-sparing surgery. Current data are not sufficient to identify the optimal procedure after NAC [abdominal radical trachelectomy (ART) or vaginal radical trachelectomy (VRT) or simple trachelectomy]. Some evidence suggests that pregnancy outcome is better after simple trachelectomy as compared with VRT or ART. Long-term results regarding oncological outcome for this concept are still lacking. Adjuvant chemotherapy in patients with histopathological risk factors (lymphovascular space involvement (LVSI), macroscopic residual disease) would decrease a risk of recurrence.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Robova H,Rob L,Halaska MJ,Pluta M,Skapa P

doi

10.1007/s11912-015-0446-0

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

446

issue

5

eissn

1523-3790

issn

1534-6269

journal_volume

17

pub_type

杂志文章,评审
  • VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.

    abstract::The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discover...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0015-5

    authors: Cowey CL,Rathmell WK

    更新日期:2009-03-01 00:00:00

  • Systemic Therapies for Advanced Squamous Cell Anal Cancer.

    abstract:PURPOSE OF REVIEW:We aim to summarise the available evidence on systemic therapies for advanced anal cancer. RECENT FINDINGS:There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, e...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0698-6

    authors: Sclafani F,Rao S

    更新日期:2018-05-04 00:00:00

  • Management of gynecological cancers during pregnancy.

    abstract::The diagnosis of a gynecological malignancy during pregnancy is rare but not uncommon. Cancer treatment during pregnancy is possible, but both maternal and fetal interests need to be respected. Different treatment plans may be justifiable and multidisciplinary treatment is advised. Clinical trials are virtually imposs...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-014-0415-z

    authors: Han SN,Verheecke M,Vandenbroucke T,Gziri MM,Van Calsteren K,Amant F

    更新日期:2014-12-01 00:00:00

  • Lung cancer screening.

    abstract::The result of a lung cancer screening program should be fewer lung cancer-specific deaths in the screened population. Studies evaluating chest imaging as a screening tool for lung cancer have not shown a reduction in lung cancer-specific mortality to date. The ability of institutions using chest imaging to meet the cr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0032-1

    authors: Mazzone PJ,Mekhail T

    更新日期:2007-07-01 00:00:00

  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

    abstract::Concurrent radiation therapy and chemotherapy is the primary treatment for patients with squamous cell tumors of the anal canal, and is also employed in the neoadjuvant setting for patients with stage II and III adenocarcinoma of the rectum. There is constant clinical study involving modifications of chemoradiotherapy...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-011-0166-z

    authors: Meyer J,Balch G,Willett C,Czito B

    更新日期:2011-06-01 00:00:00

  • Gastric carcinoma.

    abstract::Although gastric cancer is still a worldwide major public health concern, it remains relatively uncommon in the Western countries. Despite improvement in surgical morbidity and mortality, as well as significant advancement of chemotherapy and radiotherapy options, the survival for gastric cancer has not significantly ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0049-7

    authors: Phan AT,Ajani JA

    更新日期:2004-05-01 00:00:00

  • Novel agents in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma, comprising approximately 6-8% of all non-Hodgkin lymphomas. MCL is biologically and clinically heterogeneous, and there is no standard treatment for MCL. Although untreated MCL often responds well to frontline combination chemotherapy, relapsed, re...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0460-2

    authors: Kumar A

    更新日期:2015-08-01 00:00:00

  • New Directions in Vulvar Cancer Pathology.

    abstract:PURPOSE OF REVIEW:The aim of this article is to provide clinicians and pathologists with an understanding of the aetiopathology, pathogenesis and classification of vulval neoplasia and their molecular correlates. RECENT FINDINGS:There is an increased understanding of subcellular changes in vulvar malignancies. These p...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0833-z

    authors: Williams A,Syed S,Velangi S,Ganesan R

    更新日期:2019-08-15 00:00:00

  • Chemotherapy for androgen- independent prostate cancer: myth or reality.

    abstract::In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0058-0

    authors: Kelly WK,Slovin SF

    更新日期:2000-09-01 00:00:00

  • The clinical management of BRCA1 and BRCA2 mutation carriers.

    abstract::Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0008-9

    authors: Gulati AP,Domchek SM

    更新日期:2008-01-01 00:00:00

  • The changing prognosis of melanoma.

    abstract::Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article we discuss the most current information regarding prognostic factors in early-stage and advanced malignant mela...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0025-9

    authors: Buzaid AC,Anderson CM

    更新日期:2000-07-01 00:00:00

  • Success at last: a molecular factor that informs treatment.

    abstract::Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vinc...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-012-0281-5

    authors: Lassman AB

    更新日期:2013-02-01 00:00:00

  • Targeting pediatric malignancies for T cell-mediated immune responses.

    abstract::Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, mo...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0108-7

    authors: Mackall CL,Helman LJ

    更新日期:2000-11-01 00:00:00

  • Clinical development of siltuximab.

    abstract::Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, we...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0453-1

    authors: Davis CC,Shah KS,Lechowicz MJ

    更新日期:2015-07-01 00:00:00

  • The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery.

    abstract:PURPOSE OF REVIEW:The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires-completed and reviewed with patients during care delivery-are poised to play a large role in this guideline because they provide a more comprehensive underst...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0571-z

    authors: Stover AM,Basch EM

    更新日期:2017-02-01 00:00:00

  • Second-line chemotherapy for non-small-cell lung cancer.

    abstract::Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consiste...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0016-x

    authors: Fossella FV

    更新日期:2000-01-01 00:00:00

  • Value and Quality of Care in Head and Neck Oncology.

    abstract:PURPOSE OF REVIEW:The concept of value-based health care (VBHC) was articulated more than a decade ago. However, its clinical implementation remains an on-going process and a particularly demanding one for the domain of head and neck cancer (HNC). These cancers often present with fast growing tumors in functionally and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00952-5

    authors: Takes RP,Halmos GB,Ridge JA,Bossi P,Merkx MAW,Rinaldo A,Sanabria A,Smeele LE,Mäkitie AA,Ferlito A

    更新日期:2020-07-10 00:00:00

  • Fertility preservation and management of gonadal failure associated with lymphoma therapy.

    abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0039-6

    authors: Howell SJ,Shalet SM

    更新日期:2002-09-01 00:00:00

  • Targeting breast cancer with CDK inhibitors.

    abstract::Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0443-3

    authors: Mayer EL

    更新日期:2015-01-01 00:00:00

  • Postmastectomy radiation therapy.

    abstract::Many women undergo mastectomy as treatment of their breast cancer either because of personal preference or because of tumor-related factors making mastectomy the preferred surgical option. The use of postmastectomy radiation therapy has been shown to decrease the risk of local recurrence and in some cases improve over...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0361-1

    authors: Lyons JA,Sherertz T

    更新日期:2014-01-01 00:00:00

  • Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

    abstract:PURPOSE OF REVIEW:Immune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0738-2

    authors: Barroso-Sousa R,Ott PA

    更新日期:2018-11-15 00:00:00

  • Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

    abstract:PURPOSE OF REVIEW:Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety profiles, financial...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00989-6

    authors: Tabbò F,Passiglia F,Novello S

    更新日期:2021-01-02 00:00:00

  • Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.

    abstract::Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This articl...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0114-7

    authors: Petrylak DP

    更新日期:2003-05-01 00:00:00

  • Current therapy for malignant mesothelioma.

    abstract::This review briefly summarizes the results of previous systemic (chemotherapy) and local (surgery and radiotherapy) treatment attempted to date for malignant mesothelioma. The prospects for newer modalities, ie molecular and biologic therapies, are also highlighted, including results of both preclinical and early clin...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0006-2

    authors: Smythe WR

    更新日期:2002-07-01 00:00:00

  • Opioids and Chronic Pain: Where Is the Balance?

    abstract::Chronic opioid therapy (defined as greater than 3 months on opioids) is a common practice for those with non-cancer pain, cancer survivors with treatment-related pain, and individuals with cancer undergoing disease-modifying therapy with a survival that can be for a year or more. Recent studies have found unique long-...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0558-1

    authors: Davis MP,Mehta Z

    更新日期:2016-12-01 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • The Management of rNPC: Salvage Surgery vs. Re-irradiation.

    abstract:PURPOSE OF REVIEW:Treatment failure, in the form of either persistence or local recurrence, occurs in 10 to 30% of nasopharyngeal carcinoma patients after initial radiotherapy (RT). Early detection of persistent or recurrent disease aids in the recognition of tumors that can be candidates for salvage nasophayngectomy o...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00949-0

    authors: Hao CY,Hao SP

    更新日期:2020-07-09 00:00:00

  • Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

    abstract::Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor pr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0680-3

    authors: Marquina G,Manzano A,Casado A

    更新日期:2018-04-02 00:00:00

  • Prevention of radiation-induced mucositis.

    abstract::Radiation-induced mucositis is an important dose-limiting acute side effect associated with the treatment of tumors of the upper aerodigestive tract. The toxicity of radiation therapy increases with prior or concurrent administration of some chemotherapeutic agents. Pretreatment eradication of infection, maintenance o...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0043-2

    authors: Johnson JT

    更新日期:2001-01-01 00:00:00

  • Molecular diagnosis in lymphoma.

    abstract::The evolution of our ability to diagnose and classify lymphomas in an increasingly refined manner has paralleled the development of novel technologic approaches, with contemporary practice dependent upon the harnessing of a plethora of data that include microscopic, immunophenotypic, and genetic information. Although ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0063-9

    authors: Bagg A

    更新日期:2004-09-01 00:00:00